Access cutting-edge renal cell carcinoma treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access renal cell carcinoma specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related renal cell carcinoma treatment provided free
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-\[L\]1) adjuvant therapy. This substudy will
Sponsor: Merck Sharp & Dohme LLC
Check if you qualify for this renal cell carcinoma clinical trial in New York, NY
If you're searching for renal cell carcinoma treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced renal cell carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.